Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 71% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.

Johnson & Johnson breaks higher ahead of vaccine announcement

Johnson & Johnson CFO raises hopes ahead of vaccine announcement, with the EU in particular standing to gain given AstraZeneca struggles.

Johnson & Johnson could bring key tool to fighting Coronavirus

The fourth quarter was dominated by vaccine news from Moderna,Pfizer Inc, and AstraZeneca, with all three coming out with impressive data from their respective products. However, it looks like next week will provide a key update for one of the most important vaccines going forward.

Johnson & Johnson (All Sessions) has a single-dose vaccine developed under its Janssen subsidiary. Group CFO Joseph Wolk appeared on CNBC today stating that they expect ‘very robust data’ when the vaccine results are released next week. That not only provides gains for the stock, but also European markets. Given the difficulties the EU are experiencing in obtaining their allotted AstraZeneca vaccinations, a high quality product from Johnson & Johnson could be crucial to shortening the crisis in the region.

The chart below from the FT highlights the importance of this vaccine for the region. The US, Canada, EU, and New Zealand would all see substantial benefits to a good product given their pre-orders.

Johnson & Johnson: technical analysis

The Johnson & Johnson (All Sessions) chart shows the bullish breakout seen today, with traders reacting with optimism over the potential impending announcement next week. With anticipation of that announcement likely to build over the coming days, we will likely see further upside, with a bullish outlook in play unless price breaks below the $160.10 swing-low.

Act on share opportunities today

Go long or short on thousands of international stocks with spread bets and CFDs.

  • Get full exposure for a comparatively small deposit
  • Trade on spreads from just 0.1%
  • Get greater order book visibility with direct market access

See opportunity on a stock?

Try a risk-free trade in your demo account, and see whether you’re on to something.

  • Log in to your demo
  • Take your position
  • See whether your hunch pays off

See opportunity on a stock?

Don’t miss your chance – upgrade to a live account to take advantage.

  • Trade a huge range of popular stocks
  • Analyse and deal seamlessly on fast, intuitive charts
  • See and react to breaking news in-platform

See opportunity on a stock?

Don’t miss your chance. Log in to take advantage while conditions prevail.

Related articles

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

Plan your trading week

Get the week’s market-moving news sent directly to your inbox every Monday. The Week Ahead gives you a full calendar of upcoming economic events, as well as commentary from our expert analysts on the key markets to watch.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of spread betting and CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.